{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:31:28Z","timestamp":1786444288580,"version":"build-2736575974"},"reference-count":31,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15766","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:35:18Z","timestamp":1784115318000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["PRR11 expression in early ER+\/HER2\u2011low breast cancer: Association with estrogen receptor positivity and exploratory analysis of prognostic significance"],"prefix":"10.3892","volume":"32","author":[{"given":"Alper","family":"Turkel","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Irkkan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haktan","family":"Erdem","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Etlik City Hospital, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazan","family":"Bozdogan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Bahsi","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Etlik City Hospital, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"key20260811124537_b1-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1038\/s41467-020-19291-x","article-title":"Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"key20260811124537_b2-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.biocel.2012.12.002","article-title":"PRR11 is a novel gene implicated in cell cycle progression and lung cancer","volume":"45","author":"Ji","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"key20260811124537_b3-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3892\/ol.2020.11615","article-title":"PRR11 and SKA2 promote the proliferation, migration and invasion of esophageal carcinoma cells","volume":"20","author":"Chen","year":"2020","journal-title":"Oncol Lett"},{"key":"key20260811124537_b4-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"e0128943","DOI":"10.1371\/journal.pone.0128943","article-title":"PRR11 \u0131s a prognostic marker and potential oncogene in patients with gastric cancer","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"key":"key20260811124537_b5-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5483\/BMBRep.2019.52.2.207","article-title":"PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer","volume":"52","author":"Wang","year":"2019","journal-title":"BMB Rep"},{"key":"key20260811124537_b6-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/biom12121800","article-title":"PRR11 in malignancies: Biological activities and targeted therapies","volume":"12","author":"Han","year":"2022","journal-title":"Biomolecules"},{"key":"key20260811124537_b7-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20260811124537_b8-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/0115665232283880240301035621","article-title":"Efficacy and safety of pembrolizumab monotherapy or combined therapy in patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Araghi","year":"2025","journal-title":"Curr Gene Ther"},{"key":"key20260811124537_b9-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"key20260811124537_b10-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"key":"key20260811124537_b11-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20260811124537_b12-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20260811124537_b13-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2043-9113-3-13","article-title":"High-throughput identification of reference genes for research and clinical RT-qPCR analysis of breast cancer samples","volume":"3","author":"Maltseva","year":"2013","journal-title":"J Clin Bioinforma"},{"key":"key20260811124537_b14-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20260811124537_b15-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.7150\/jca.29265","article-title":"The oncogenic potential of PRR11 gene in tongue squamous cell carcinoma cells","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"key20260811124537_b16-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gendis.2021.02.012","article-title":"PRR11 induces filopodia formation and promotes cell motility via recruiting ARP2\/3 complex in non-small cell lung cancer cells","volume":"9","author":"Wei","year":"2022","journal-title":"Genes Dis"},{"key":"key20260811124537_b17-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"877320","DOI":"10.3389\/fmolb.2022.877320","article-title":"PRR11 promotes cell proliferation by regulating PTTG1 through interacting with E2F1 transcription factor in pan-cancer","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"key20260811124537_b18-ol-32-3-15766","first-page":"1760","article-title":"RNAi-mediated silencing of praline-rich gene causes growth reduction in human lung cancer cells","volume":"8","author":"Zhao","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20260811124537_b19-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"key":"key20260811124537_b20-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clbc.2022.02.008","article-title":"Characteristics, clinical differences and outcomes of breast cancer patients with negative or low HER2 expression","volume":"22","author":"Rosso","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"key20260811124537_b21-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"16719","DOI":"10.1038\/s41598-023-43186-8","article-title":"Tumor characteristics and survival rate of HER2-low breast cancer patients: A retrospective cohort study","volume":"13","author":"Abbasvandi","year":"2023","journal-title":"Sci Rep"},{"key":"key20260811124537_b22-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s12282-023-01487-w","article-title":"Prognosis difference between HER2-low and HER2-zero breast cancer patients: A systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Breast Cancer"},{"key":"key20260811124537_b23-ol-32-3-15766","first-page":"133","article-title":"PRR11 immunoreactivity is a weak prognostic factor in non-mucinous invasive adenocarcinoma of the lung","volume":"109","author":"Sakai","year":"2017","journal-title":"Pathologica"},{"key":"key20260811124537_b24-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.3892\/ol.2017.5974","article-title":"Expression of PRR11 protein and its correlation with pancreatic cancer and effect on survival","volume":"13","author":"Tan","year":"2017","journal-title":"Oncol Lett"},{"key":"key20260811124537_b25-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.21873\/anticanres.16625","article-title":"Prognostic value of HER2-low status in ER+ early breast cancer: A systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2023","journal-title":"Anticancer Res"},{"key":"key20260811124537_b26-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00508-023-02315-z","article-title":"Prognostic factors in non-metastatic HER2 \u2018low\u2019 and HER2 \u2018negative\u2019 breast cancer: Single institute experience","volume":"136","author":"T\u00fcrkel","year":"2024","journal-title":"Wien Klin Wochenschr"},{"key":"key20260811124537_b27-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40944-023-00713-9","article-title":"Proline-rich protein 11 overexpression in \u0131nvasive breast carcinoma: A potential diagnosis biomarker","volume":"21","author":"Anouar Tadlaoui","year":"2023","journal-title":"Indian J Gynecol Oncolog"},{"key":"key20260811124537_b28-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.gendis.2017.12.003","article-title":"Silencing of PRR11 suppresses cell proliferation and induces autophagy in NSCLC cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Genes Dis"},{"key":"key20260811124537_b29-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.cellsig.2014.08.019","article-title":"The role of PI3K\/AKT\/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration","volume":"26","author":"Heras-Sandoval","year":"2014","journal-title":"Cell Signal"},{"key":"key20260811124537_b30-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"300060520927919","DOI":"10.1177\/0300060520927919","article-title":"The PI3K\/AKT\/mTOR pathway regulates autophagy to induce apoptosis of alveolar epithelial cells in chronic obstructive pulmonary disease caused by PM2.5 particulate matter","volume":"48","author":"Zhang","year":"2020","journal-title":"J Int Med Res"},{"key":"key20260811124537_b31-ol-32-3-15766","doi-asserted-by":"publisher","first-page":"e70295","DOI":"10.1002\/mco2.70295","article-title":"PI3K\/AKT\/mTOR axis in cancer: From pathogenesis to treatment","volume":"6","author":"Jiang","year":"2025","journal-title":"MedComm (2020)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:45:42Z","timestamp":1786441542000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15766","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}